Mergers and acquisitions – Page 2
-
BusinessDSM and Firmenich to merge
Flavour and fragrance-focused Firmenich complements DSM’s transition away from traditional chemicals
-
BusinessPharmaceuticals roundup 2021
It’s been another dramatic, pandemic-dominated year for the pharmaceutical industry
-
BusinessMorphosys agrees to buy cancer epigenetics specialist Constellation
$1.7bn deal will be funded by selling rights to royalties on existing drugs
-
BusinessShell to sell US refinery stake to Mexican state-owned petroleum company
Pemex will take full control of Deer Park refinery, as Mexico’s president moves to gain energy independence
-
BusinessGovernment clears merger of SinoChem and ChemChina
China’s chemicals giants will unite under a state-run holding company
-
BusinessBiggest venture yet of any pharma company into cannabis
Jazz Pharmaceuticals buys cannabinoid therapeutic firm for $7.2 billion, inheriting first plant-derived cannabinoid medicine ever approved by FDA
-
BusinessChemicals industry roundup 2020
Pandemic provides impetus to re-tune supply chains for resilience and sustainability
-
BusinessPharmaceuticals roundup 2020
Alongside the race for Covid-19 treatments and vaccines, the industry has maintained momentum
-
BusinessAstraZeneca to buy rare disease drugmaker Alexion in $39bn deal
Transaction would be the largest in AstraZeneca’s history
-
BusinessIneos to buy BP petrochemicals businesses for $5bn
Deal covers 14 acetyls and aromatics manufacturing plants and 10 joint ventures
-
BusinessBayer commits over $10bn to resolve legacy Monsanto lawsuits
Agreement settles about 75% of Roundup-related cases and resolves PCB and dicamba litigation
-
BusinessPharmaceuticals roundup 2019
Under the shadow of political turmoil and major lawsuits, the industry returned to its strengths – making new drugs, and finding new ways to do it better
-
BusinessChemicals industry roundup 2019
Focus turns to sustainability amid rising economic pressures and political uncertainty
-
BusinessPfizer’s Upjohn to merge with Mylan
Deal combines Pfizer’s off-patent drug portfolio with Mylan’s generics
-
BusinessUS judges slash damages in glyphosate cancer lawsuits
While upholding rulings linking the herbicide to cancer, judges have cut Bayer-Monsanto’s fines from billions to tens of millions of dollars
-
BusinessAbbVie to acquire Allergan in multibillion-dollar merger
Takeover deal will create world’s fifth-largest pharma company
-
OpinionIs Bayer regretting its Monsanto takeover?
Large damages in Roundup litigation have got investors questioning the move
-
BusinessJury awards $2bn damages in US glyphosate trial
Bayer vows to appeal third defeat over Monsanto’s Roundup weedkiller, while experts suggest damages will likely be reduced
-
BusinessPower-hungry Tesla picks up supercapacitor maker
Maxwell Technologies deal highlights potential for supercapacitors in electric vehicles and beyond
-
